|
Parameters
|
Entire cohort (N = 901)
|
Common (n = 366)
|
Severe (n = 411)
|
Critical (n = 124)
|
P value
|
|---|
|
Age, years (median, IQR)
|
60.0 (49.0–69.0)
|
54.0 (42.8–62.0)
|
64.0 (52.0–71.0)
|
68.5 (58.0–78.0)
|
< 0.001
|
|
Sex-n, %
|
0.015
|
|
Male
|
435 (48.3)
|
161 (44.0)
|
201 (48.9)
|
73 (58.9)
| |
|
Female
|
466 (51.7)
|
205 (56.0)
|
210 (51.1)
|
51 (41.1)
| |
|
Coexisting disorders-n, %
|
509 (56.5)
|
171 (46.7)
|
245 (59.6)
|
93 (75.0)
|
< 0.001
|
|
Hypertension
|
289 (32.1)
|
82 (22.4)
|
149 (36.3)
|
58 (46.8)
|
< 0.001
|
|
Diabetes mellitus
|
126 (14.0)
|
38 (10.4)
|
57 (13.9)
|
31 (25.0)
|
< 0.001
|
|
Chronic obstructive lung disease
|
17 (1.9)
|
3 (0.8)
|
7 (1.7)
|
7 (5.6)
|
< 0.001
|
|
Hemorrhagic or ischemic stroke
|
38 (4.2)
|
6 (1.6)
|
15 (3.6)
|
17 (13.7)
|
< 0.001
|
|
History of tuberculosis
|
13 (1.4)
|
4 (1.1)
|
5 (1.2)
|
4 (3.2)
|
0.002
|
|
Autoimmune diseases
|
10 (1.1)
|
4 (1.1)
|
4 (1.0)
|
2 (1.6)
|
0.49
|
|
Chronic kidney disease
|
13 (1.4)
|
0 (0)
|
3 (0.7)
|
10 (8.1)
|
< 0.001
|
|
Malignancies
|
22 (2.4)
|
8 (2.2)
|
13 (3.2)
|
1 (0.8)
|
0.30
|
|
Coronary artery disease
|
73 (8.1)
|
18 (4.9)
|
37 (9.0)
|
18 (14.5)
|
0.002
|
|
Chronic dialysis
|
7 (0.8)
|
0 (0)
|
2 (0.5)
|
5 (4.0)
|
< 0.001
|
|
Baseline IL-6
|
< 0.001
|
|
Normal-n, %
|
708 (78.6)
|
347 (94.8)
|
329 (80.0)
|
32 (25.8)
| |
|
Elevateda-n, %
|
193 (21.4)
|
19 (5.2)
|
82 (20.0)
|
92 (74.2)
| |
|
Tocilizumab used-n, %
|
16 (1.8)
|
4 (1.1)
|
7 (1.7)
|
5 (4)
|
0.39
|
|
Outcomesb-n, %
|
< 0.001
|
|
Cured/discharged
|
683 (75.8)
|
290 (79.2)
|
340 (82.7)
|
53 (42.7)
|
< 0.001
|
|
Continued hospitalization
|
193 (21.4)
|
76 (20.8)
|
70 (17.0)
|
47 (37.9)
|
< 0.001
|
|
Death
|
24 (2.7)
|
0 (0)
|
0 (0)
|
24 (19.4)
|
< 0.001
|
- aHigher than upper limit of normal
- b1 missing data in the severe group
